Cargando…
Aberrant Promoter Hypomethylation in CLL: Does It Matter for Disease Development?
Over the last 30 years, studies of aberrant DNA methylation in hematologic malignancies have been dominated by the primary focus of understanding promoter hypermethylation. These efforts not only resulted in a better understanding of the basis of epigenetic silencing of tumor suppressor genes but al...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980682/ https://www.ncbi.nlm.nih.gov/pubmed/27563627 http://dx.doi.org/10.3389/fonc.2016.00182 |